Breast Carcinoma Clinical Trial
Official title:
Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer With 0-3 Positive Axillary Lymph Nodes
This research trial studies quality of life, employment, and informal care cost analysis in patients with breast cancer receiving chemotherapy. This trial assesses how quality of life has been affected by cancer, if cancer and its treatment have caused in changes in the patient's or their spouse's employment and how they have affected the patient and their extended family, and the impact of peripheral neuropathy caused by chemotherapy on quality of life. Learning about quality of life and informal care costs may help doctors better understand how patients feel during treatment, what effects the medicines are having, and in the future may help both patients and doctors as they decide which medicines to use to treat cancer.
PRIMARY OBJECTIVES:
I. To compare the individual treatment arms relative to the degree that symptoms interfere
with patient functioning and to characterize and compare the relative duration that symptoms
interfere with patient functioning.
II. To assess the employment consequences of cancer and its treatment on the patient and
extended family, and to compare treatment arms relative to these consequences.
III. To determine the prevalence and severity of peripheral neuropathy in breast cancer
patients treated by adjuvant chemotherapy with dose dense (every two weeks) paclitaxel for 4
cycles, from study entry to 5 years after the start of treatment.
SECONDARY OBJECTIVES:
I. To identify baseline characteristics that are predictive for patients being more
vulnerable to experiencing side effects which significantly interfere with patient
functioning.
II. To identify and characterize the relative importance of the reasons that patients decide
to participate in the treatment study (Cancer and Leukemia Group B [CALGB] 40101) and how
those reasons might change as a consequence of their experience with treatment.
III. To compare the quality-adjusted life years between adjuvant chemotherapy (AC) and
paclitaxel or between short and long schedules, regardless of the other factor.
IV. To measure, over the course of adjuvant therapy, the type and amount of informal care
needs of the patient.
V. Using a societal perspective, estimate and compare the economic consequences on employment
and informal care needs.
VI. To determine if specific identifiable clinical adverse events (i.e., neuropathy or
fatigue) are associated with greater economic consequences.
VII. To examine factors which are predictive of a patient being employed during and after
cancer treatment.
VIII. To compare the prevalence and severity of peripheral neuropathy in breast cancer
patients treated by dose dense paclitaxel to those patients treated with dose dense CA
(cyclophosphamide and doxorubicin).
IX. To conduct an exploratory examination of the relationship between the severity of
peripheral neuropathy after paclitaxel treatment (4 and 6 cycles) and breast cancer patients'
functioning, including physical, psychological, and social functioning.
X. To validate the neurotoxicity items in the Symptoms in Relation to Patient Functioning
Survey (C-1271) used in this protocol by correlating its results with the Functional
Assessment of Cancer Therapy (FACT)-Neurotoxicity Subscale (C-669) and the European
Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ)-Core (C)30 and Breast Cancer module (C-259 and C-618).
OUTLINE:
Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire,
Medical Outcome Study (MOS) Social Support Survey, Patient Preferences, CALGB Background
Information, and European Quality of Life 5-Dimensions (EQ-5D) and QOL Assessment Form;
Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX
subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the
cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the
Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30,
EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48,
and 60 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04996316 -
MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
|
||
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT05526872 -
A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening
|
N/A | |
Not yet recruiting |
NCT05178498 -
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
|
||
Recruiting |
NCT05544123 -
The Treatment Situation of Chinese County Population With Breast Cancer
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Completed |
NCT01422408 -
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy
|
Phase 2 | |
Terminated |
NCT02810873 -
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT00770354 -
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT03185871 -
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
|
Phase 2 | |
Completed |
NCT02983279 -
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT05406232 -
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
|
||
Recruiting |
NCT03408353 -
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
|
||
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Terminated |
NCT02923037 -
Hatha Yoga in Breast Cancer Survivors
|
N/A |